Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review

Tiago Costa de Pádua(Universidade Federal de São Paulo), Andrea Necchi(Vita-Salute San Raffaele University), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Alberto Martini(The University of Texas MD Anderson Cancer Center), Luigi Nocera(Istituti di Ricovero e Cura a Carattere Scientifico), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Marco Moschini(Vita-Salute San Raffaele University), Laura Marandino, Francesco Montorsi(Vita-Salute San Raffaele University), Filippo Pederzoli(Cornell University)
Urologic Oncology Seminars and Original Investigations
August 13, 2022
10.1016/j.urolonc.2022.07.006
Cited by 29

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656